- Poster presentation
- Open Access
Large differences in variability for genes associated with antimalarial drug resistance between samples from Tanzania and Ethiopia
© Golassa et al; licensee BioMed Central Ltd. 2014
- Published: 22 September 2014
- Antimalarial Drug
- Variable Part
- Artemisinin Combination Therapy
- Chloroquine Resistance
Changes in antimalarial drug policy lead to selection of the most successful parasite clones. In spite of a change to Artemisinin Combination Therapy (ACT), we have earlier shown a low degree of variability for the chloroquine resistance marker pfcrt in samples of Plasmodium falciparum from Ethiopia with 100% carrying the crucial K76T variant .
The study material was collected in the Shalla district, Oromia, Ethiopia, and in different parts of Tanzania. Genetic polymorphisms in the genes pfmdr1 and pfubp1 were analysed by PCR and nucleotide sequence determinations.
A surprising finding was that a majority of Ethiopian isolates carried the wild type variant of pfmdr1. The majority of samples from different regions of Tanzania were wild type for both pfcrt and pfmdr1. Analysis of a variable linker region in pfmdr1 showed substantial variation in samples from Tanzania, but minimal variation in samples from Ethiopia. The variable part consists of consecutive NDN residues. The dominating variant in Ethiopians was 7/2/9 and 7/2/10 in Tanzania. The same pattern was seen for a variable part of the pfubp1 gene, where all Ethiopian samples were identical to 3D7. In 19 Tanzanian samples only 8 were identical to 3D7 with 5 other variants. A polymorphism at codon 1528, detected previously in Kenyan samples  was found in 2 Tanzanian samples.
While the presence of the mutant variant of pfcrt in the Ethiopian samples can be explained by continued use of chloroquine in Ethiopia for treatment of P. vivax, the selection of wild type pfmdr1 could be a consequence of using ACT for treatment of P. falciparum. In general, the variability in both studied genes was greater in Tanzania than in Ethiopia. There are no data yet to link the variability in pfubp1 to efficacy of ACT.
- Golassa L, Enweji N, Erko B, Aseffa A, Swedberg G: High prevalence of pfcrt-CVIET haplotype in isolates from asymptomatic and symptomatic patients in south-central Oromia, Ethiopia. Malaria J. 2014, 13: 120-10.1186/1475-2875-13-120.View ArticleGoogle Scholar
- Borrmann S: Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Sci Rep. 2013, 3: 3318-PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.